What is BIIB's current stock price?

As of now, BIIB is trading at $149.17, with a daily change of -0.61%.

What are the risks associated with BIIB stock?

BIIB Key risk is its Low Risk Level, .

What is BIIB next earnings date?

BIIB next earnings report is scheduled for Oct 29, 2025.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Earnings Calendar Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

BIIB Stock Analysis & IQ Rating | Biogen

BIIB

Biogen

$149.17

-$0.91 | -0.61%

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Headlines

52W High

$ 187.58

MKT CAP

$ 22.04B

52W Low

$ 110.04

VOL

$ 787.06K

P/E Ratio

14.27

AVG VOL

$ 1.67M

RSI

56.37

TREND

Uptrend

BIIB Stock IQ

Login to see Biogen (BIIB) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

BIIB Target Price

Login to display

Strengths

BIIB Rewards

Earnings are forecast to grow

BIIB Rewards

Trading below its fair value

BIIB Rewards

Outperform the market

Chart

$137.37 (+8.59%)

$129.52 (+15.17%)

$131.84 (+13.14%)

$174.4 (-14.47%)

1year

6month

3month

1month

BIIB Risk Level

BIIB has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

LOW

HIGH

BIIB Analysts Opinion

BIIB overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

BIIB Analysts Opinion

BIIB Analysts opinion is negative and it remained unchanged from the past 3 months

BIIB Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

69%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

40%

50%

BIIB Street Opinion

BIIB Street view is bullish but have mixed views on the near-term outlook

BIIB Performance Sentiment

Sentiments overview associated with BIIB events and the stock performance.

69%

31%

Positive

Negative

11 out of 16
events present

5 out of 16
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$147.71

Resistance
Price

$135.67

Current Price Range

$159.88

Show methods +

BIIB Earnings

The TTM reflects 12-month period, providing review of BIIB financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

9,997

9,676

9,836

+0.82%

Cost of Revenue

2,457

2,310

2,533

-1.51%

Gross Profit

7,541

7,366

7,302

+1.62%

Operating Exp

5,133

5,147

5,471

-3.14%

Operating Inc

2,408

2,219

1,831

+14.68%

Net Interest Inc

-166

-183

30

-

Interest Exp

252

250

247

+1.01%

Interest Inc

86

68

277

-44.28%

Other Inc Exp

-444

-130

-564

-

EPS Growth

10.15

11.21

8.02

+12.50%

BIIB Financial Health

The company financial health has moderately improved over the past year

Financial Score

3.57

Next Earnings Date: Oct 29, 2025

Linked to BIIB

IQ

Close Price

Change

AMGN

3.99

291.67

-0.42%

SCLX

2.75

16.64

+14.05%

CHRS

3.50

1.67

-0.30%

ALVO

2.25

8.35

+2.39%

BIIB Latest Analysis +

Biogen Vanqua ink licensing deal worth up to $1B for immunology drug.

Today

$150.17 | +0.06%

Activity

Will Biogen Beat on Q3 Earnings? Leqembi Skyclarys Could Hold the Key. Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.

Today

$150.17 | +0.06%

Activity

Momentum

Potential

Biogen Inks License Deal For Vanqua Bios Oral C5aR1 Antagonist . (RTTNews) - Biogen Inc. (BIIB) Friday announced a license agreement granting the company exclusive worldwide rights to Chicago-based Vanqua Bios preclinical oral C5aR1 antagonist which is designed to modulate neutrophil-driven inflammation.

Today

$150.17 | +0.06%

Activity

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?. Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Thu Oct 23, 2025

$150.08 | +1.60%

Earnings

J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround. Key PointsFlorida-based J. L. Bainbridge sold 119376 shares of Biogen for an estimated $16.1 million in the third quarter.

Mon Oct 20, 2025

$146.69 | +2.54%

Activity

Why InnoCares Licensing Deal Triggered A Stock Rout.

Thu Oct 16, 2025

$142.26 | -0.97%

Activity

Momentum

Biogen sees negative impact on Q3 EPS from IPR&D expense.

Tue Oct 14, 2025

$145.31 | +0.43%

Potential

7 Analysts Have This To Say About Biogen. 7 analysts have shared their evaluations of Biogen (NASDAQ:BIIB) during the recent three months expressing a mix of ish and bearish perspectives.The following table provides a quick overview of their recent ratings highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.2140000100100000010011200Analysts have set 12-month price targets for Biogen revealing an average target of $164.14 a high estimate of $219.0

Fri Oct 10, 2025

$146.57 | -2.03%

Activity

Biogen And Stoke Therapeutics Present Promising Long-Term Data For Zorevunersen In Dravet Syndrome . (RTTNews) - Biogen Inc. (BIIB) and Stoke Therapeutics Inc. (STOK) unveiled new long-term follow-up data from ongoing open-label extension (OLE) studies of zorevunersen reinforcing its potential as a disease-modifying treatment for Dravet syndrome. The findings were presented at

Fri Oct 10, 2025

$146.57 | -2.03%

Activity

Monday Sector Laggards: Healthcare Consumer Products. The worst performing sector as of midday Monday is the Healthcare sector showing a 0.6% loss. Within that group Biogen Inc (Symbol: BIIB) and Baxter International Inc (Symbol: BAX) are two of the days laggards showing a loss of 4.1% and 2.8% respectively. Among healthcare

Mon Oct 6, 2025

$154.05 | -3.65%

Momentum

FAQ About BIIB Stock Insights

What is BIIB current stock price?

What are BIIB stock strengths?

What risks are associated with BIIB stock?

When is BIIB next earnings report?

What is BIIB market cap and volume?

What is BIIB's current Stock IQ?

Should I buy BIIB stock right now?

Is BIIB a Strong Buy right now?

What does a 'Strong Buy' rating mean for BIIB?

What does a 'Strong Sell' rating mean for BIIB?

What factors influence BIIB's Stock IQ?

Explore our BIIB Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored BIIB Stock Strategies
Effective Risk Management

FIND US ON

Receive our BIIB Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

BIIB

Biogen

Current Price

$149.17

-$0.91 | -0.61%

52W High

$ 187.58

MKT CAP

$ 22.04B

52W Low

$ 110.04

VOL

$ 787.06K

P/E Ratio

14.27

AVG VOL

$ 1.67M

RSI

56.37

TREND

Uptrend

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

BIIB Rewards

Earnings are forecast to grow

BIIB Rewards

Trading below its fair value

BIIB Rewards

Outperform the market

Linked to BIIB

Symbol

IQ

Close

Change

AMGN

3.99

291.67

-0.42%

SCLX

2.75

16.64

+14.05%

CHRS

3.50

1.67

-0.30%

ALVO

2.25

8.35

+2.39%

BIIB Stock IQ

Login to unlock Biogen (BIIB) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$137.37 (+8.59%)

$129.52 (+15.17%)

$131.84 (+13.14%)

$174.4 (-14.47%)

1year

6month

3month

1month

BIIB Analysts Opinion

BIIB Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

BIIB Analysts Opinion

BIIB Analysts opinion is negative and it remained unchanged from the past 3 months

BIIB Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

69%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

40%

50%

BIIB Street Opinion

BIIB Street view is bullish but have mixed views on the near-term outlook

BIIB Risk Level

BIIB has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

LOW

HIGH

BIIB Performance Sentiment

Sentiments overview associated with BIIB events and the stock performance.

69%

31%

Positive

Negative

11 out of 16
events present

5 out of 16
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$147.71

Resistance
Price

$135.67

Current Price Range

$159.88

Show methods +

BIIB Earnings

The TTM data reflects the most recent 12-month period, providing overview of BIIB financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

9,997

9,676

9,836

+0.82%

Cost of Revenue

2,457

2,310

2,533

-1.51%

Gross Profit

7,541

7,366

7,302

+1.62%

Operating Exp

5,133

5,147

5,471

-3.14%

Operating Inc

2,408

2,219

1,831

+14.68%

Net Interest Inc

-166

-183

30

-

Interest Exp

252

250

247

+1.01%

Interest Inc

86

68

277

-44.28%

Other Inc Exp

-444

-130

-564

-

EPS Growth

10.15

11.21

8.02

+12.50%

BIIB Financial Health

The company financial health has moderately improved over the past year

Financial Score

3.57

Next Earnings Date: Oct 29, 2025

BIIB Latest Analysis

Biogen Vanqua ink licensing deal worth up to $1B for immunology drug.

Today

$150.17 | +0.06%

Activity

Will Biogen Beat on Q3 Earnings? Leqembi Skyclarys Could Hold the Key. Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.

Today

$150.17 | +0.06%

Activity

Momentum

Potential

Biogen Inks License Deal For Vanqua Bios Oral C5aR1 Antagonist . (RTTNews) - Biogen Inc. (BIIB) Friday announced a license agreement granting the company exclusive worldwide rights to Chicago-based Vanqua Bios preclinical oral C5aR1 antagonist which is designed to modulate neutrophil-driven inflammation.

Today

$150.17 | +0.06%

Activity

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?. Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Thu Oct 23, 2025

$150.08 | +1.60%

Earnings

J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround. Key PointsFlorida-based J. L. Bainbridge sold 119376 shares of Biogen for an estimated $16.1 million in the third quarter.

Mon Oct 20, 2025

$146.69 | +2.54%

Activity

Why InnoCares Licensing Deal Triggered A Stock Rout.

Thu Oct 16, 2025

$142.26 | -0.97%

Activity

Momentum

Biogen sees negative impact on Q3 EPS from IPR&D expense.

Tue Oct 14, 2025

$145.31 | +0.43%

Potential

7 Analysts Have This To Say About Biogen. 7 analysts have shared their evaluations of Biogen (NASDAQ:BIIB) during the recent three months expressing a mix of ish and bearish perspectives.The following table provides a quick overview of their recent ratings highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.2140000100100000010011200Analysts have set 12-month price targets for Biogen revealing an average target of $164.14 a high estimate of $219.0

Fri Oct 10, 2025

$146.57 | -2.03%

Activity

Biogen And Stoke Therapeutics Present Promising Long-Term Data For Zorevunersen In Dravet Syndrome . (RTTNews) - Biogen Inc. (BIIB) and Stoke Therapeutics Inc. (STOK) unveiled new long-term follow-up data from ongoing open-label extension (OLE) studies of zorevunersen reinforcing its potential as a disease-modifying treatment for Dravet syndrome. The findings were presented at

Fri Oct 10, 2025

$146.57 | -2.03%

Activity

Monday Sector Laggards: Healthcare Consumer Products. The worst performing sector as of midday Monday is the Healthcare sector showing a 0.6% loss. Within that group Biogen Inc (Symbol: BIIB) and Baxter International Inc (Symbol: BAX) are two of the days laggards showing a loss of 4.1% and 2.8% respectively. Among healthcare

Mon Oct 6, 2025

$154.05 | -3.65%

Momentum

Discover BIIB Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of BIIB. We're here to help you make informed investment decisions today.

FIND US ON

Receive our BIIB Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

BIIB Stock trends

BIIB Stock performance

BIIB Stock analysis

BIIB investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing BIIB

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing BIIB

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

BIIB Stock Analysis & IQ Rating | Biogen

BIIB Stock IQ

BIIB Target Price

BIIB Risk Level

BIIB Analysts Opinion

BIIB Street Consensus

BIIB Performance Sentiment

Technical Price Levels

BIIB Financial Health

Explore our BIIB Stock insights

Receive our BIIB Daily Alerts

BIIB Stock IQ

BIIB Street Consensus

BIIB Risk Level

Technical Price Levels

Discover BIIB Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of BIIB. We're here to help you make informed investment decisions today.

Receive our BIIB Daily Alerts

BIIB Runner Alarm